FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223487031> ?p ?o ?g. }

• W4223487031 endingPage "214" @default.
• W4223487031 startingPage "205" @default.
• W4223487031 abstract "The PRO.M.E.THE.O. study (PredictiOn Models in Ent cancer for anti-EGFR based THErapy Optimization) aimed to develop a predictive model (PM) of overall survival (OS) for patients with locally advanced oropharyngeal cancer (LAOC) treated with radiotherapy (RT) and cetuximab (Cet) from an Italian dataset.We enrolled patients with LAOC from 6 centres treated with RT-Cet. Clinical and treatment variables were collected. Patients were randomly divided into training (TS) (80%) and validation (VS) (20%) sets. A binary logistic regression model was used on the TS with stepwise feature selection and then on VS. Timepoints of 2, 3 and 5 years were considered. The area under the curve (AUC) of receiver operating characteristic of 2, 3 and 5 year and confusion matrix statistics at 5-threshold were used as performance criteria.Overall, 218 patients were enrolled and 174 (79.8%) were analysed. Age at diagnosis, gender, ECOG performance, clinical stage, dose to high-risk volume, overall treatment time and day of RT interruption were considered in the final PMs. The PMs were developed and represented by nomograms with AUC of 0.75, 0.73 and 0.73 for TS and 0.713, 0.713, 0.775 for VS at 2, 3 and 5 years, respectively.PRO.M.E.THE.O. allows the creation of a PM for OS in patients with LAOC treated with RT-Cet.Sviluppo di un modello predittivo in pazienti affetti da neoplasia dell’orofaringe: PRO.M.E.THE.O.L’obiettivo di PRO.M.E.THE.O. è quello di sviluppare modelli predittivi (MP) di sopravvivenza globale (OS) per pazienti (pz) con neoplasia orofaringea localmente avanzata (LAOC) sottoposti a radioterapia (RT) e Cetuximab (Cet), provenienti da un dataset italiano multicentrico.Sono stati arruolati pazienti con LAOC trattati con RT-Cet provenienti da 6 centri italiani, dei quali sono state raccolte variabili cliniche e di trattamento. I pazienti sono stati suddivisi casualmente in un training set (80%) e in un gruppo di controllo (20%). Per la creazione del MP è stata considerata l’OS a 2, 3 e 5 anni. L’area sottesa alla curva (AUC) di ROC (receiver operating characteristic) a 2, 3 e 5 anni e la statistica della matrice di confusione a 5 classi rappresentano i criteri di performance.218 pazienti sono stati arruolati e 174 (79,8%) analizzati. I parametri testati per la costruzione degli MP includevano: età alla diagnosi, sesso, ECOG, stadio clinico, dose del volume ad alto rischio, tempo complessivo di trattamento e giorni di interruzione della RT. I MP di OS sono stati rappresentati con dei nomogrammi.PRO.M.E.THE.O. ha consentito la creazione di MP di OS in pazienti LAOC trattati con RT-Cet." @default.
• W4223487031 created "2022-04-15" @default.
• W4223487031 creator A5007199024 @default.
• W4223487031 creator A5008208200 @default.
• W4223487031 creator A5009624503 @default.
• W4223487031 creator A5019407140 @default.
• W4223487031 creator A5026203664 @default.
• W4223487031 creator A5039841257 @default.
• W4223487031 creator A5043752638 @default.
• W4223487031 creator A5045186426 @default.
• W4223487031 creator A5046747849 @default.
• W4223487031 creator A5048586661 @default.
• W4223487031 creator A5050834286 @default.
• W4223487031 creator A5051064975 @default.
• W4223487031 creator A5053408500 @default.
• W4223487031 creator A5054019294 @default.
• W4223487031 creator A5060509370 @default.
• W4223487031 creator A5063661270 @default.
• W4223487031 creator A5071515814 @default.
• W4223487031 creator A5088004393 @default.
• W4223487031 creator A5088956472 @default.
• W4223487031 date "2022-06-01" @default.
• W4223487031 modified "2023-10-18" @default.
• W4223487031 title "Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O." @default.
• W4223487031 cites W1967358484 @default.
• W4223487031 cites W2006940889 @default.
• W4223487031 cites W2043453187 @default.
• W4223487031 cites W2061036339 @default.
• W4223487031 cites W2081582681 @default.
• W4223487031 cites W2098324585 @default.
• W4223487031 cites W2151730005 @default.
• W4223487031 cites W2155384808 @default.
• W4223487031 cites W2155760602 @default.
• W4223487031 cites W2165066626 @default.
• W4223487031 cites W2170165091 @default.
• W4223487031 cites W2194286561 @default.
• W4223487031 cites W2522342451 @default.
• W4223487031 cites W2566074209 @default.
• W4223487031 cites W2742417192 @default.
• W4223487031 cites W2749434790 @default.
• W4223487031 cites W2808106850 @default.
• W4223487031 cites W2864789400 @default.
• W4223487031 cites W2894796681 @default.
• W4223487031 cites W2901263658 @default.
• W4223487031 cites W2901385432 @default.
• W4223487031 cites W2990982374 @default.
• W4223487031 cites W3000936329 @default.
• W4223487031 cites W3122285725 @default.
• W4223487031 cites W4233026002 @default.
• W4223487031 doi "https://doi.org/10.14639/0392-100x-n1672" @default.
• W4223487031 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35396587" @default.
• W4223487031 hasPublicationYear "2022" @default.
• W4223487031 type Work @default.
• W4223487031 citedByCount "0" @default.
• W4223487031 crossrefType "journal-article" @default.
• W4223487031 hasAuthorship W4223487031A5007199024 @default.
• W4223487031 hasAuthorship W4223487031A5008208200 @default.
• W4223487031 hasAuthorship W4223487031A5009624503 @default.
• W4223487031 hasAuthorship W4223487031A5019407140 @default.
• W4223487031 hasAuthorship W4223487031A5026203664 @default.
• W4223487031 hasAuthorship W4223487031A5039841257 @default.
• W4223487031 hasAuthorship W4223487031A5043752638 @default.
• W4223487031 hasAuthorship W4223487031A5045186426 @default.
• W4223487031 hasAuthorship W4223487031A5046747849 @default.
• W4223487031 hasAuthorship W4223487031A5048586661 @default.
• W4223487031 hasAuthorship W4223487031A5050834286 @default.
• W4223487031 hasAuthorship W4223487031A5051064975 @default.
• W4223487031 hasAuthorship W4223487031A5053408500 @default.
• W4223487031 hasAuthorship W4223487031A5054019294 @default.
• W4223487031 hasAuthorship W4223487031A5060509370 @default.
• W4223487031 hasAuthorship W4223487031A5063661270 @default.
• W4223487031 hasAuthorship W4223487031A5071515814 @default.
• W4223487031 hasAuthorship W4223487031A5088004393 @default.
• W4223487031 hasAuthorship W4223487031A5088956472 @default.
• W4223487031 hasBestOaLocation W42234870311 @default.
• W4223487031 hasConcept C121608353 @default.
• W4223487031 hasConcept C126322002 @default.
• W4223487031 hasConcept C143998085 @default.
• W4223487031 hasConcept C146357865 @default.
• W4223487031 hasConcept C151730666 @default.
• W4223487031 hasConcept C151956035 @default.
• W4223487031 hasConcept C170964787 @default.
• W4223487031 hasConcept C2779998722 @default.
• W4223487031 hasConcept C2989005 @default.
• W4223487031 hasConcept C34626388 @default.
• W4223487031 hasConcept C509974204 @default.
• W4223487031 hasConcept C526805850 @default.
• W4223487031 hasConcept C58471807 @default.
• W4223487031 hasConcept C71924100 @default.
• W4223487031 hasConcept C86803240 @default.
• W4223487031 hasConceptScore W4223487031C121608353 @default.
• W4223487031 hasConceptScore W4223487031C126322002 @default.
• W4223487031 hasConceptScore W4223487031C143998085 @default.
• W4223487031 hasConceptScore W4223487031C146357865 @default.
• W4223487031 hasConceptScore W4223487031C151730666 @default.
• W4223487031 hasConceptScore W4223487031C151956035 @default.
• W4223487031 hasConceptScore W4223487031C170964787 @default.
• W4223487031 hasConceptScore W4223487031C2779998722 @default.

• next